Dayvigo Accelerated Titration: How to Titrate Lemborexant Safely

What the FDA Label Says About Lemborexant Dosing

The prescribing information for Dayvigo is straightforward. The recommended starting dose is 5 mg taken orally once per night, within five minutes of going to bed, with at least seven hours of intended sleep remaining 1. If 5 mg is tolerated but does not produce adequate symptom control, the dose may be increased to 10 mg nightly 1.

No Mandatory Titration Interval

Unlike some CNS medications that specify week-by-week escalation schedules, the lemborexant label does not mandate a minimum number of nights at 5 mg before moving to 10 mg. The label language reads: "dose can be increased to a maximum recommended dose of 10 mg" based on clinical response 1. This gives prescribers discretion to escalate as early as the first follow-up, provided the patient reports tolerability at 5 mg.

The 5 mg Starting Point Is Not Optional

The label does not permit initiating therapy at 10 mg. Every patient begins at 5 mg. This is a meaningful distinction from zolpidem extended-release, where certain populations start at different doses based on sex. For lemborexant, 5 mg is the universal entry point regardless of age or sex 1.

CYP3A Inhibitors Change the Ceiling

Patients taking moderate CYP3A inhibitors (such as fluconazole or verapamil) should not exceed 5 mg nightly. Strong CYP3A inhibitors make lemborexant contraindicated entirely 1. This pharmacokinetic constraint effectively eliminates the possibility of dose escalation in a subset of patients, a point clinicians should verify before planning any titration.

SUNRISE-1: The Key Trial Behind Both Doses

SUNRISE-1 was a randomized, double-blind, placebo-controlled, phase III trial enrolling 1,006 adults aged 55 years and older with insomnia disorder. The trial tested lemborexant at 5 mg and 10 mg against placebo over 30 nights, using polysomnography (PSG) as the primary objective measure 2.

Sleep Onset Results

At the primary endpoint of one month, lemborexant 10 mg reduced latency to persistent sleep (LPS) by a mean of 10.5 minutes compared to placebo (P<0.001). The 5 mg dose reduced LPS by 7.6 minutes versus placebo (P<0.001) 2. Both doses reached statistical significance, but the 10 mg arm showed a numerically larger effect size on sleep onset.

Sleep Maintenance Results

Wake after sleep onset (WASO) decreased by 22.0 minutes with 10 mg and 15.0 minutes with 5 mg compared to placebo at the first-month assessment (both P<0.001) 2. The difference between the two active arms was roughly 7 minutes on WASO, a clinically perceptible gap for patients who wake repeatedly during the night.

What This Means for Titration Decisions

SUNRISE-1 did not include a titration arm where patients started at 5 mg and then escalated. Participants were randomized directly to a fixed dose. The trial therefore confirms that both doses work, and that 10 mg provides incrementally greater benefit on objective PSG measures. It does not, by itself, tell prescribers how long to wait before escalating 2.

How Clinicians Typically Approach Dose Escalation in Practice

Real-world titration of lemborexant follows patterns shaped by the drug's pharmacokinetics, patient-reported outcomes, and the prescriber's clinical judgment rather than a rigid protocol.

The 7-to-14-Night Reassessment Window

Most sleep medicine specialists reassess after one to two weeks at 5 mg. Seven nights provides enough exposure to evaluate both efficacy and side effects beyond the first-night adjustment period. Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at the University of California, San Francisco, has noted in clinical commentary that "with DORAs, you can generally gauge the therapeutic signal within the first week, because the mechanism does not require receptor downregulation or neuroplastic adaptation" 3.

Patient-Reported Sleep Diary Drives the Decision

Objective PSG is rarely repeated outside of research settings. In practice, escalation decisions rely on patient sleep diaries and validated instruments like the Insomnia Severity Index (ISI). A commonly used threshold: if the ISI score remains above 14 (moderate insomnia) after 7 to 14 nights at 5 mg, and the patient reports no next-morning drowsiness or somnolence, escalation to 10 mg is reasonable 4.

Same-Night Pharmacokinetics Support Rapid Assessment

Lemborexant reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours and has a half-life of 17 to 19 hours 1. Steady state is reached within about 4 to 5 days of nightly dosing. This means a patient on 5 mg for seven nights has had at least two to three days at full steady-state exposure, giving the clinician a reliable picture of the drug's effect at that dose.

Step-by-Step Accelerated Titration Protocol

The following protocol reflects a condensed but evidence-informed approach to moving from 5 mg to 10 mg. It is not a substitute for individualized clinical judgment, and each step assumes the prescriber has ruled out CYP3A interactions and other contraindications.

Night 1 Through Night 7: Establish Baseline Response

Begin lemborexant 5 mg nightly. Instruct the patient to take the tablet within five minutes of getting into bed, with no food consumed within the prior two hours (high-fat meals delay absorption by approximately 1.5 hours) 1. Ask the patient to keep a sleep diary recording bedtime, estimated sleep onset latency, number of awakenings, total sleep time, and any morning grogginess.

Day 7 to Day 10: Reassessment

Review the sleep diary at or after day 7. The key questions are binary. First: did the patient tolerate 5 mg without next-day somnolence, dizziness, or sleep paralysis? Second: does the patient still meet insomnia thresholds (ISI score above 14, or self-reported sleep onset latency above 30 minutes, or WASO above 30 minutes on most nights)?

If the answer to both is yes, escalation to 10 mg is appropriate. If the patient reports morning sedation or other adverse effects at 5 mg, do not escalate.

Night 8 Onward (If Escalating): Move to 10 mg

Switch directly from 5 mg to 10 mg. No intermediate dose exists. There is no 7.5 mg tablet, and the tablets should not be split 1. Reassess again at day 14 (one week on the new dose) to confirm improved efficacy without emergent side effects.

If 10 mg Is Insufficient

Lemborexant's ceiling is 10 mg. There is nowhere to titrate beyond this. If 10 mg does not produce adequate benefit after two to four weeks, the American Academy of Sleep Medicine (AASM) clinical practice guideline recommends reassessing the insomnia diagnosis, screening for comorbid conditions (such as obstructive sleep apnea or restless legs syndrome), and considering cognitive behavioral therapy for insomnia (CBT-I) as a first-line alternative or adjunct 5.

Safety Considerations During Dose Escalation

Somnolence and Next-Day Impairment

In SUNRISE-1, somnolence occurred in 10% of the lemborexant 10 mg group compared to 6% at 5 mg and 1% with placebo 2. This dose-dependent increase is the primary safety signal that clinicians should monitor when escalating. The 17-to-19-hour half-life means residual plasma concentrations persist into the following morning, particularly during the first few days after a dose increase.

The FDA label includes a specific warning: patients should be cautioned against driving or operating heavy machinery until they know how 10 mg affects them the following day 1. Prescribers should repeat this warning at the point of escalation, not only at initiation.

Sleep Paralysis and Hypnagogic Hallucinations

Because lemborexant blocks orexin receptors (the same signaling pathway disrupted in narcolepsy type 1), dose-dependent narcolepsy-like symptoms can occur. Sleep paralysis was reported in 1% to 2% of patients at 10 mg in pooled clinical trial data 1. Patients should be told that brief episodes of inability to move upon waking, while alarming, are a recognized pharmacological effect and not a neurological emergency.

Hepatic Impairment Alters the Effective Dose

Patients with mild hepatic impairment (Child-Pugh A) require no adjustment. Moderate hepatic impairment (Child-Pugh B) reduces clearance enough that the maximum recommended dose drops to 5 mg, effectively removing the option of dose escalation 1. Severe hepatic impairment is a contraindication. Liver function should be assessed before planning any titration in patients with known hepatic disease.

Concurrent CNS Depressants

Alcohol, benzodiazepines, opioids, and other CNS depressants can amplify the sedative effects of lemborexant. The AASM guideline on pharmacologic treatment of chronic insomnia states: "Clinicians should avoid combining orexin receptor antagonists with other CNS depressants unless the benefit clearly outweighs the additive risk of respiratory depression and excessive sedation" 5. This caution applies at both 5 mg and 10 mg but becomes more clinically significant after escalation.

Lemborexant vs. Other DORAs: Titration Differences

Suvorexant (Belsomra) Comparison

Suvorexant is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets, offering a wider titration range 6. The recommended starting dose is 10 mg, with a maximum of 20 mg. Suvorexant's longer effective half-life (approximately 12 hours, but with active metabolites extending the pharmacodynamic effect) and its four-tier dosing scheme mean titration is inherently more gradual. Lemborexant's two-tier system makes escalation a single binary decision.

Clinical Implication

For patients who want rapid dose optimization, lemborexant's simpler structure is an advantage. There is one escalation decision, and it can happen within 7 to 14 days. Suvorexant may require multiple step-ups across weeks.

Special Populations and Titration Adjustments

Older Adults

SUNRISE-1 enrolled adults aged 55 and older, so both the 5 mg and 10 mg doses have direct efficacy and safety data in this population 2. No dose adjustment is required based on age alone. Older adults are more susceptible to falls related to nighttime sedation. The prescriber should confirm that the patient's home environment minimizes fall risk before moving to 10 mg.

Patients With Comorbid Depression or Anxiety

Insomnia frequently co-occurs with mood and anxiety disorders. A post hoc analysis of SUNRISE-2 (the 12-month extension trial) demonstrated that lemborexant maintained efficacy in patients with comorbid depressive symptoms without worsening mood scores 7. Dose escalation in these patients follows the same general protocol, though clinicians should monitor for any change in mood or suicidal ideation, as the FDA label carries a general CNS-depressant warning applicable to all sleep medications.

Shift Workers and Non-Standard Sleep Schedules

The FDA label specifies that lemborexant should be taken when a patient can devote at least seven hours to sleep. For shift workers with variable schedules, dose escalation should only be considered once the patient has established a consistent sleep window, because irregular timing confounds the assessment of drug efficacy versus circadian misalignment 1.

When Not to Escalate

Some patients should stay at 5 mg indefinitely. The 5 mg dose produced statistically significant improvements in both LPS and WASO in SUNRISE-1. A patient who reports "mostly better" sleep with minimal residual complaints may not benefit enough from 10 mg to justify the incremental somnolence risk. The goal is consolidated sleep, not maximal receptor occupancy.

Patients who report morning drowsiness at 5 mg should not escalate. The appropriate step is to evaluate timing (is the patient taking the dose too late?), food intake (did a heavy meal delay absorption?), and drug interactions before concluding that 5 mg itself is the problem 1.

If the patient is on a moderate CYP3A inhibitor, 5 mg is the ceiling. Period.